Trial Profile
Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2023
Price :
$35
*
At a glance
- Drugs Dimethyl fumarate (Primary) ; Peginterferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TEC-GISTRY
- Sponsors Biogen
- 27 Apr 2023 Results of Final Analysis of Pregnancy Outcomes (As of 13 May 2022, n=397 ), presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 17 Jun 2022 Status changed from recruiting to completed.
- 22 Apr 2021 Interim analysis (as of 08 April 2020, n=345) presented at the 73rd Annual Meeting of the American Academy of Neurology